NGHIÊN CỨU NỒNG ĐỘ PIVKA-II HUYẾT TƯƠNG Ở BỆNH NHÂN UNG THƯ BIỂU MÔ TẾ BÀO GAN CÓ AFP BÌNH THƯỜNG

Abstract

Objectives: To evaluate the plasma PIVKA-II (protein induced by vitamin K absence or antagonists II) concentration and its correlation with certain tumor characteristics and disease stages in patients with hepatocellular carcinoma (HCC) who have normal AFP (alpha-fetoprotein) levels. Methods: A cross-sectional descriptive, analytical study was conducted on 51 patients with normal AFP levels diagnosed with HCC, treated at Military Hospital 103 and Military Central Hospital 108. Plasma PIVKA-II was quantified using a fluorescent microsphere immunoassay on the Architect ci16200 machine. Results: The median plasma PIVKA-II concentration in patients with normal AFP levels was 89.22 mAU/mL, with elevated PIVKA-II > 40 mAU/mL found in 78.4% of patients. There was a statistically significant correlation between plasma PIVKA-II concentration and the tumor size, as well as portal vein thrombosis status, in patients with normal AFP levels. Conclusion: Elevated plasma PIVKA-II is observed in patients with HCC and is associated with tumor burden, indicating that it is a useful marker for the diagnosis and prognosis of HCC with normal AFP levels.